[1] 张立洁,王欣欣,孟忻. 慢性HBsAg携带者及非活动性HBV感染状态的病理学研究. 临床肝胆病杂志,2007,23(5):337-339. [2] 刘耕陶,斯崇文,王勤环. 对我国慢性病毒性肝炎防治与研究工作的建议. 中华医学杂志,2002,82(2):13-18. [3] Liaw YF. Natural history of chronic hepatitis B infection and long-term outcome under treatment. Liver Int,2009,29(suppl1):100-107. [4] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8(6):324-329. [5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [6] 叶立红,梅志勤,刘彦超,等. 162例慢性HBV携带者HBV DNA载量与肝组织炎症坏死程度的相关性. 临床肝胆病杂志,2007,23(5):27-32. [7] 张小东. 浅谈乙肝表面抗原携带者的诊疗及预后.现代中西医结合杂志,2008,15(3):411-412. [8] Zhang M,He W,Liu F,et al. Inhibition of mouse hepatocyte apoptosis via anti-Fas ribozyme. World J Gastroenterol,2004, 10(17):412-418. [9] Choudhury JA,Ruessel CL,Randhaws S,et al.Differential induction of nuclear Factor-KB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. Mol Boil Cell,2003,44:1334-1341. [10] Ockner RK. Apoptosis and liver disease:recent concepts of mechanism and significance. J Gastroenterol Hepatol,2001,16:248-260. [11] 马清峰,王威. 慢性乙型肝炎患者IL-18、Fas检测的临床意义.实用医学杂志,2010,26(7):1181-1182. [12] 宋修光,马立宪. 乙型肝炎患者肝细胞Fas和血清可溶性s Fas与肝脏损伤的关系. 临床检验杂志,2007,25(1):32-33. [13] 盛云建,宋新文. 慢性乙型肝炎患者外周血淋巴细胞Fas表达和凋亡的检测及意义. 中国煤炭工业医学杂志,2008,11(3):317-318. [14] 邢文斌,刘丽娜,吕申. Fas、FasL在慢性乙型肝炎患者肝细胞和外周血淋巴细胞上的表达. 临床肝胆病杂志,2007,23(1):11-13. [15] Jun EJ,Han JY,Sun HS. Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B. Korean J Hepatol,2006,12(4):507-514. [16] Lapinski TW. The concentration of Fas in the serum and liver tissue in viral chronic hepatitis B patients treated with lamivudine. Hepatogastroenterology,2005,52(62):575-579. [17] Oksuz M,Akkiz H,Isiksal YF,et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol,2004,16(3):341-345. [18] Song le H,Binh VQ,Duy DN,et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol,2004,73(2):244-249. [19] Lee JY, Chae DW,Kim SM,et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat,2004,11(2):130-135. [20] Jung YJ,Kim YJ,Kim LH,et al. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology,2007,50(5):369-376. |